Masimo CEO Joe Kiani ousted from board; Politan wins two seats
Sep 19, 2024 · Masimo, best known for its litigation with Apple over the company’s use of pulse-oximetry technology in the Apple Watch, sued Politan, alleging errors in its proxy statement. The activist, in...
What’s next at Masimo after CEO Kiani’s exit? | MedTech Dive
Sep 30, 2024 · Masimo’s leadership transition brings a two-year boardroom feud to a close, but questions remain about the path forward in the wake of CEO Joe Kiani’s exit. Kiani resigned after losing his board seat in a Sept. 19 shareholder vote, ending his tenure 35 years after founding the pulse oximetry firm.
Masimo is Executing a Successful Strategy to Deliver Long-Term ...
Aug 15, 2024 · Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry ...
Masimo CEO shared confidential information with investor ahead …
Sep 6, 2024 · Masimo CEO Joe Kiani, whose medical-technology company is in the midst of a proxy battle with activist Politan, revealed what he called confidential information to a major investor 12 hours...
Masimo - Masimo Has the Right Leadership and Strategy to Drive …
Aug 26, 2024 · Masimo Has the Right Leadership and Strategy to Drive Long-Term Value Creation. August 26, 2024. Highlights Risk to Continued Momentum and Innovation if Politan Gains Board Control. Urges Stockholders to Vote “FOR” Only Masimo’s Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card.
Masimo - Masimo Board of Directors Files Definitive Proxy and …
Jun 17, 2024 · Strongly Encourages Stockholders to Vote FOR Joe Kiani and Christopher Chavez on the GOLD Proxy Card. Warns Stockholders of Politan’s Value-Destructive Agenda Should It Gain Control. Highlights Masimo’s Track Record of Innovation, Longstanding Premium Valuation, Strong Long-Term Plan and Superior Director Nominees.
Masimo (MASI) Receives a Buy from Piper Sandler - Markets Insider
3 days ago · The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Masimo with a $166.25 average price target, a 16.30% upside from current levels.
Masimo - Masimo Announces Preliminary Second Quarter 2024 …
Jun 29, 2024 · View All News. Masimo Corporation (Nasdaq: MASI) today announced preliminary revenue and select financial results for the second quarter ended June 29, 2024. Preliminary Second Quarter 2024 Revenue and Select Financial Results: Consolidated revenue is expected to be approximately $496 million, representing 9% growth on a reported basis and 10% ...
Masimo Appoints Timothy Scannell and Wendy Lane to Board of …
3 days ago · IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company’s ...
News & Media - 2022 - Masimo
Masimo Announces Limited Market Release of Sepsis Index. Breakthrough Early Warning Solution, for Integration with Masimo Patient SafetyNet™, Is Designed to Help Clinicians Catch Deterioration in Patient Condition